Add To Watchlist
Share URL
About The Company
Description
GuiZhou SanLi Pharmaceutical Co.
Read More
Overview
Value
10
Growth
76
Health
61
Management
85
Analyst Opinion
80
Total
62
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Has a low level of debt
- Low risk of bankruptcy
- Has strong financial health
- Liked by analysts
- Has strong dividend growth
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Price-to-earnings ratio of 40.3 is higher than the market average (19.6x)
- Very safe dividend
Market Peers
603439.SS
Key Figures
PE Ratio (TTM)
40.25
Margin Of Safety (DCF)
-46.51%
Revenue Growth (5 Year Average)
19.13%
Ratings Consensus
Buy
Share Buybacks
-3.77%
Dividend Yeild (TTM)
0.12%
Valuation
Value Score
10
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 4.8 CNY ✘
Current Price: 14.9 CNY
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
40.25x
Free Cashflow Yeild
1.66%
PE/Earnings Growth
0.74
Price/Book
5.36x
Growth
Growth Score
76
- ✔ 5 Year Average Revenue growth of 19.13% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 19.42% is higher than the market average (14.48%)
- ✔ 5 Year Average Cashflow growth of 24.87% is higher than the market average (12.35%)
- ✔ Free Cashflow growth has improved this year
- ✘ Earnings growth has slowed this year
Revenue Growth
19.13%
Earnings Growth
19.42%
Cashflow Growth
24.87%
Health
Health Score
61
Altman Z Score
9.54
Piostroski Score
4.00
Debt/Equity
0.19x
Current Assets/Liabilities
3.05x
Free Cashflow/Total Debt
0.64x
Debt/Capital
0.18x
Dividend
Secure Dividend Score
91
- ✔ Very safe
- ✔ Long term dividend payout ratio of 34.72% is considered good
- ✔ Payout ratio (TTM) of 4.97% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✔ Dividend growth has been accelerating recently
- ✔ Spending a lower percentage of their income on dividends than last 5 years
- ✘ Dividend yeild of 0.12% is less than the market average (1.85%)
Dividend Yeild
0.12%
Dividend Growth
40.65%
Payout Ratio (Earnings)
4.97%
Payout Ratio (Cashflow)
7.18%
Management
Management Score
85
- ✔ Has issued new shares to finance growth when share price is high
- ✔ Has returned higher dividends when earnings have risen
- ✔ Return-on-capital-employed of 11.95% is higher than the market average (10%)
- ✘ Has a history of diluting shareholders to finance activity
- ✘ Return-on-equity of 14.70% is lower than the market average (15%)
Average Buybacks/Dilution
-3.77%
Recent Buybacks/Dilution
-0.42%
5 Year Price Volitility
36.42%
Return On Assets
10.79%
Return On Capital Employed
11.95%
Return On Equity
14.70%
Return On Free Cashflow
1314.17%
Return On Investments
127.30%
Analysts
Analyst Opinion
80
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
GuiZhou SanLi Pharmaceutical Co.,Ltd
Currency
CNY
Beta
0.966266
Vol Avg
22304265
Ceo
Hai Zhang
Cik
Cusip
Exchange
Shanghai
Full Time Employees
1007
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2020-04-28
Address
Xiayun Industrial Park
City
Guiyang
State
Country
CN
Zip
561100
Phone
86 851 3811 3572
All financial data provided by FMP